Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-β1, and TGF-β type II receptor interact to inhibit the growth of pituitary lactotropes

Endocrinology

Volumn 146, Issue 10, 2005, Pages 4179-4188

  Sarkar, D K ^a   Chaturvedi, K ^a   Oomizu, S ^a   Boyadjieva, N I ^a   Chen, C P ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE; DOPAMINE 2 RECEPTOR; ISOPROTEIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; MITOSIS INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; RAT; REGULATORY MECHANISM; TUMOR GROWTH;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BROMOCRIPTINE; CELLS, CULTURED; DOPAMINE; ESTRADIOL; FEMALE; HYPOTHALAMIC HORMONES; OVARIECTOMY; PITUITARY GLAND, ANTERIOR; RATS; RATS, INBRED F344; RECEPTORS, DOPAMINE D2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 24944465618     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2005-0430     Document Type: Article

References (44)

1. MacLeod RM, Scapagnini U, Thorner MO 1980 Pituitary microadenomas. New York: Academic Press; 683-855
2. Tonner D, Schlechte J 1993 Contemporary therapy of prolactin-secreting adenomas. Am J Med Sci 306:395-397
3. Colao A, Annunziato L, Lombardi G 1998 Treatment of prolactinomas. Ann Med 30:452-459
4. Sarkar DK, Gottschall PE, Meites J 1982 Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting pituitary tumors. Science 218:684-686
5. Asa SL, Kelly MA, Grandy DK, Low ML 1999 Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 140:5348-5355
6. Ben-Jonathan N, Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724-763
7. Enjalbert A, Musset F, Chenard C, Priam M, Kordon C, Heisler S 1988 Dopamine inhibits prolactin secretion stimulated by the calcium channel agonist Bay-K-8644 through a pertussis toxin-sensitive G protein in anterior pituitary cells. Endocrinology 123:406-412
8. Gregerson KA, Flagg TP, O'Neill TJ, Anderson M, Lauring O, Horel JS, Welling PA 2001 Identification of G protein-coupled, inward rectifier potassium channel gene products from the rat anterior pituitary gland. Endocrinology 142:2820-2832
9. Taussig R, Gilman AG 1995 Mammalian membrane-bound adenylyl cyclases. J Biol Chem 270:1-4
10. Yan G, Chen X, Bancroft C 1994 A constitutively active form of CREB can activate expression of the rat prolactin promoter in non-pituitary cells. Mol Cell Endocrinol 101:R25-R30
11. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK, Low MJ 1997 Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19:103-113
12. Saiardi A, Bozzi Y, Baik JH, Borrelli E 1997 Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 19:115-126
13. Bosse R, Fumagalli F, Jaber M, Giros B, Gainetdinov RR, Wetsel WC, Missale C, Caron MG 1997 Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron 19:127-138
14. Laccarino C, Samad TK, Mathis C, Kercret H, Picetti R, Borrelli E 2002 Control of lactotrope proliferation by dopamine: essential role of signaling through D2 receptors ERKs. Proc Soc Nat Acad Sci USA 99:14530-14535
15. Sarkar DK, Kim KH, Minami S 1992 Transforming growth factor-β1 mRNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol 6:1825-1833
16. 125]TGFβ1-binding sites. J Endocrinol 149:19-27
17. Pastorcic M, De A, Boyadjieva N, Vale W, Sarkar DK 1995 Reduction in the expression and action of transforming growth factor β1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary. Cancer Res 55:4892-4898
18. Páez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grübler Y, Chervin A, Goldberg V, Goya R, Hentges S, Low M, Holsboer F, Stalla GK, Artz E 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Soc Natl Acad Sci USA 100:1034-1039
19. Hentges S, Sarkar DK 2001 Transforming growth factor-β regulation of estradiol-induced prolactinomas. Front Neuroendocrinol 22:340-363
20. Shida N, Ikeda H, Yoshimoto T, Oshima M, Taketo MM, Miyoshi I 1998 Estrogen-induced tumorigenesis in the pituitary gland of TGFβ(+/-) knockout mice. Biochim Biophys Acta 1407:79-83
21. Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh MB 1998 Role of TGFβ type I and TGFβ type II receptors in the TGFβ1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology 138:3620-3628
22. Hentges S, Pastorcic M, De A, Boyadjieva N, Sarkar DK 2000 Opposing actions of two transforming growth factor-β isoforms on pituitary lactotropic cell proliferation. Endocrinology 141:1528-1535
23. Hentges S, Boyadjieva N, Sarkar DK 2000 Transforming growth factor-β3 stimulates lactotrope cell growth by increasing basic fibroblast growth factor from folliculo-stellate cells. Endocrinology 141:859-867
24. Heid CA, Stevens J, Livak KJ, Williams PM 1996 Real time quantitative PCR. Genome Res 6:986-994
25. Oomizu S, Boyadjieva N, Sarkar DK 2003 Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor mRNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Alcohol Clin Exp Res 27:975-980
26. Plotsky PM, Gibbs DM, Neill JD 1978 Liquid chromatographic- electrochemical measurement of dopamine in hypophysial stalk blood of rats. Endocrinology 102:1887-1894
27. Close FT, Freeman ME 1997 Effects of ovarian steroid hormones on dopamine-controlled prolactin secretory response in vitro. Neuroendocrinology 65:430-435
28. Johansen PW, Haug E, Gautvik KM 1985 Effects of bromocriptine on hormone production and cell growth in cultures rat pituitary cells. Acta Endocrinol (Copenh) 110:200-206
29. Gruszka A, Pawlikowski M, Kunert-Radek J 2001 Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects. Neuroendocrinol Lett 22:343-348
30. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG 1998 Dopamine receptors: from structure to function. Physiol Rev 78:189-225
31. Coya R, Alvarez CV, Perez F, Gianzo C, Dieguez C 1999 Effects of TGFβ1 on prolactin synthesis and secretion: an in vitro study. J Neuroendocrinol 11:351-360
32. Geyer SJ, Schanberg SM 1982 Dopamine β-hydroxylase: determination of half-life and appearance in lymph fluid after IV injection of 125 I-DBH into rats. Life Sci 30:1087-1100
33. Barton AC, Black LE, Sibley DR 1991 Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. Mol Pharmacol 39:650-658
34. Wiens BL, Nelson CS, Neve KA 1998 Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol Pharmacol 54:435-444
35. Guivarc'h D, Vincent JD, Vernier P 1998 Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology 139:4213-4221
36. Enjalbert A, Bockaert J 1983 Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 23:576-584
37. Martinez de la Escalera G, Guthrie J, Weiner RI 1988 Transient removal of dopamine potentiates the stimulation of prolactin release by TRH but not VIP: stimulation via Ca2+/protein kinase C pathway. Neuroendocrinology 47:38-45
38. Geiser AG, Kim SJ, Roberts AB, Sporn MB 1991 Characterization of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol 11:84-92
39. Pastorcic M, Sarkar DK 1997 Down-regulation of TGFβ1 gene expression in anterior pituitary cells treated with forskolin. Cytokine 9:106-111
40. Takeuchi Y, Miyamoto E, Fukunaga K 2002 Activation of the rat dopamine D2 receptor promoter by mitogen-activated protein kinase and Ca2+/calmodulin- dependent protein kinase II pathways. J Neurochem 83:784-796
41. Chaturvedi K, Sarkar DK 2004 Involvement of PKC dependent p44/42 MAP kinase signaling pathway for cross-talk between estradiol and TGFβ3 in increasing bFGF in folliculostellate cells. Endocrinology 145:706-715
42. Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, Detrick B, Hooks JJ 2003 Transforming growth factor-β induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol 197:453-462
43. Labrie F, Beaulieu M, Caron MG, Raymond V 1978 The adenohypophyseal dopamine receptor: specificity and modulation by estradiol. In: Robin C, Harter M, eds. Progress in prolactin physiology and pathology. Amsterdam: Elsevier/North-Holland; 121-132
44. Raymond V, Beaulieu M, Labrie F 1978 Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200:1173-1175